Magnesium Citrate

Description

Major Lemon is a pharmaceutical product with a designation from the Center for Drug Evaluation and Research (CDER) dated October 25, 2023. The specific details regarding its chemical composition, molecular weight, dosage form, and inactive ingredients are not provided in the extracted facts. Further information may be required to fully characterize the product's formulation and intended use.

Uses and Indications

This drug is indicated for the relief of occasional constipation (irregularity). It generally produces a bowel movement within 1/2 to 6 hours of administration.

Limitations of Use: There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The medication should be shaken well before use. It is recommended that patients drink a full glass (8 ounces) of liquid with each dose to ensure proper administration.

For adults and children aged 12 years and older, the dosage ranges from 6.5 to 10 fluid ounces, with a maximum limit of 10 fluid ounces within a 24-hour period.

For children aged 6 to under 12 years, the dosage is between 3 to 7 fluid ounces, not exceeding 7 fluid ounces in a 24-hour period.

For children aged 2 to under 6 years, the recommended dosage is 2 to 3 fluid ounces within a 24-hour timeframe, with a maximum of 3 fluid ounces in that period.

For children under 2 years of age, it is advised to consult a doctor for appropriate dosing recommendations.

The medication may be administered as a single daily dose or divided into multiple doses, depending on the clinical judgment of the healthcare provider.

Contraindications

Use of this product is contraindicated in patients experiencing rectal bleeding or failure to have a bowel movement after use, as these may indicate a serious underlying condition requiring medical evaluation. Additionally, this product should be administered at least 2 hours before or after other medications, as laxatives may interfere with the efficacy of concurrent drug therapies.

Warnings and Precautions

Patients with a history of kidney disease should exercise caution when using this medication, as it may exacerbate their condition. Additionally, individuals on a magnesium-restricted diet must be aware of the potential for increased magnesium levels, which could lead to serious complications.

Abdominal pain, nausea, or vomiting may occur during treatment. If these symptoms arise, it is advisable to consult a healthcare professional. Furthermore, patients should be vigilant for any sudden changes in bowel habits that persist for more than two weeks, as this may indicate an underlying issue requiring medical evaluation. Prolonged use of laxatives, specifically beyond one week, should also be avoided unless directed by a healthcare provider.

Patients are instructed to discontinue use and contact their doctor immediately if they experience rectal bleeding or fail to have a bowel movement after using the medication, as these symptoms could signify a serious medical condition.

In the event of an overdose, it is critical to seek emergency medical assistance or contact a Poison Control Center without delay to ensure appropriate management and care.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this product. Serious adverse reactions include rectal bleeding and failure to have a bowel movement after use, which may indicate a serious underlying condition. In such cases, patients are advised to stop use and consult a healthcare professional immediately.

Common adverse reactions may include abdominal pain, nausea, or vomiting. Patients with a history of kidney disease or those on a magnesium-restricted diet should exercise caution when using this product. Additionally, patients should be aware of any sudden changes in bowel habits that persist for more than two weeks, as well as the risks associated with prolonged laxative use exceeding one week.

Before using this product, patients are encouraged to consult a doctor or pharmacist if they are taking any other medications, as laxatives may influence the efficacy of concurrent drug therapies.

Drug Interactions

Taking this product concurrently with other medications is not recommended. It is advised that this product be administered at least 2 hours before or after other drugs to minimize potential interactions.

Laxatives may influence the efficacy of other medications. Therefore, caution should be exercised when using laxatives in conjunction with this product, as they may alter the absorption and overall effectiveness of concomitant therapies. Monitoring for therapeutic outcomes and potential side effects is recommended when these agents are used together.

Packaging & NDC

Below are the non-prescription pack sizes of Magnesium Citrate (major magnesium citrate oral solution - lemon). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may receive a maximum dosage of 3 to 7 fluid ounces within a 24-hour period, with a strict limit of 7 fluid ounces. For children aged 2 to under 6 years, the recommended dosage is 2 to 3 fluid ounces in a 24-hour period, not exceeding 3 fluid ounces. For infants under 2 years of age, it is advised to consult a healthcare professional before administration.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is no specific data available regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment may require careful consideration regarding dosing adjustments and monitoring. In individuals with reduced kidney function, particularly those with kidney disease, it is essential to assess renal clearance to ensure appropriate therapeutic levels are maintained. Additionally, patients on a magnesium-restricted diet should be monitored closely, as renal impairment can affect magnesium levels and overall electrolyte balance. Regular evaluation of renal function is recommended to guide treatment decisions and minimize the risk of adverse effects.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the context of overdosage, it is important to note that there is currently no specific information available regarding the effects or management of an overdose for this medication. Healthcare professionals are advised to exercise caution and consider the individual patient's circumstances when faced with a potential overdosage scenario.

In the absence of detailed overdosage data, it is recommended that healthcare providers monitor the patient closely for any unusual symptoms or adverse reactions. Supportive care should be initiated as necessary, and symptomatic treatment should be provided based on the clinical presentation of the patient.

In cases of suspected overdosage, it is prudent to consult local poison control centers or relevant medical authorities for guidance on management strategies tailored to the specific situation.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center in the event of an overdose. It is crucial for patients to understand the importance of stopping the use of this product and consulting a doctor if they experience rectal bleeding or fail to have a bowel movement after use, as these symptoms may indicate a serious underlying condition.

Patients should also be encouraged to consult with their healthcare provider or pharmacist prior to using this product if they are currently taking any other medications. It is important to inform patients that they should take this product at least 2 hours before or after taking other drugs, as laxatives may influence the effectiveness of other medications.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at temperatures ranging from 46° to 86°F (8° to 30°C) to maintain its efficacy and safety. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature range to prevent degradation.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Magnesium Citrate, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)